Published in J Infect Dis on October 08, 2002
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol (2009) 2.11
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ (2008) 1.99
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol (2004) 1.59
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun (2004) 1.13
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol (2012) 0.95
Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health (2014) 0.91
Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J (2005) 0.91
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. Clin Infect Dis (2015) 0.90
Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol (2007) 0.89
Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist (2011) 0.89
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother (2013) 0.89
Immunisation of premature infants. Arch Dis Child (2006) 0.86
Prospects for eradication of meningococcal disease. Arch Dis Child (2012) 0.86
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol (2006) 0.85
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child (2007) 0.84
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin Vaccine Immunol (2006) 0.84
Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG. PLoS One (2011) 0.83
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child (2006) 0.79
Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults. Clin Vaccine Immunol (2011) 0.78
Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination. Clin Infect Dis (2015) 0.76
Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient? Hum Vaccin Immunother (2015) 0.75
Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine. PLoS One (2015) 0.75
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (2010) 12.43
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet (2009) 4.07
Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol (2003) 3.73
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ (2002) 3.01
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ (2013) 2.89
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine (2005) 2.81
The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines (2012) 2.79
Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ (2013) 2.74
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med (2011) 2.59
Pneumococcal vaccination in developing countries. Lancet (2006) 2.45
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (2003) 2.30
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis (2005) 2.29
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. J Infect Dis (2006) 2.10
The impact of early behavior disturbances on academic achievement in high school. Pediatrics (2009) 2.03
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis (2009) 2.02
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect (2009) 1.89
Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med (2013) 1.84
Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. J Clin Microbiol (2011) 1.82
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis (2007) 1.79
Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ (2009) 1.75
Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med (2013) 1.74
Increasing hospital admissions for pneumonia, England. Emerg Infect Dis (2008) 1.72
Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ (2002) 1.71
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis (2007) 1.64
Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol (2003) 1.64
Wired for wellness: e-interventions for addressing college drinking. J Subst Abuse Treat (2005) 1.61
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol (2008) 1.58
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine (2012) 1.56
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol (2003) 1.53
Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis (2006) 1.53
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One (2011) 1.52
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics (2004) 1.48
Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England. Dev Med Child Neurol (2014) 1.48
Continence care for obese nursing home residents. Urol Nurs (2010) 1.48
A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS One (2012) 1.47
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill (2016) 1.46
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol (2013) 1.46
Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. Med J Aust (2012) 1.45
Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine (2007) 1.44
Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem (2001) 1.44
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect (2012) 1.43
Male reproductive control of women who have experienced intimate partner violence in the United States. Soc Sci Med (2010) 1.43
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine (2008) 1.43
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis (2010) 1.41
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab (2002) 1.40
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Characteristics of natural mentoring relationships from the perspectives of homeless youth. J Child Adolesc Psychiatr Nurs (2013) 1.38
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun (2003) 1.36
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health (2007) 1.36
Autolysin-targeted LightCycler assay including internal process control for detection of Streptococcus pneumoniae DNA in clinical samples. J Med Microbiol (2004) 1.34
Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. J Urol (2002) 1.33
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerg Infect Dis (2011) 1.31
Reproductive coercion: connecting the dots between partner violence and unintended pregnancy. Contraception (2010) 1.31
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30